新诺威(300765.SZ)拟11亿元收购巨石生物29%股权

Core Viewpoint - The company plans to acquire a 29% stake in Giant Biopharmaceutical Co., Ltd. from Enbip Pharmaceutical Co., Ltd. for 1.1 billion yuan, increasing its ownership in Giant Biopharmaceutical from 51% to 80% [1] Group 1: Transaction Details - The transaction involves a cash purchase of 1.1 billion yuan for the 29% stake in Giant Biopharmaceutical [1] - Upon completion of the transaction, the company's stake in Giant Biopharmaceutical will rise from 51% to 80% [1] Group 2: Strategic Implications - The acquisition aligns with the company's strategic shift towards the biopharmaceutical innovation sector, aiming to establish a leading innovative biopharmaceutical platform [1] - Giant Biopharmaceutical has developed a competitive R&D system and a promising product pipeline in the biopharmaceutical innovation field, with significant progress in the development and commercialization of multiple products [1] - The company views Giant Biopharmaceutical as a crucial growth engine and believes that acquiring the minority stake will enhance its business layout, implement its development strategy, and promote sustainable growth [1]